Business Description
Rhythm Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US76243J1051
Compare
Compare
Traded in other countries / regions
RYTM.USA1RV.GermanyRYTM.Mexico Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2017-10-05Description
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 81.4 | |||||
| Equity-to-Asset | 0.42 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 4.54 | |||||
| Beneish M-Score | -4.14 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 1.1 | |||||
| 3-Year EPS without NRI Growth Rate | -1.7 | |||||
| 3-Year FCF Growth Rate | 5.2 | |||||
| 3-Year Book Growth Rate | -8.8 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 94.12 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.18 | |||||
| 9-Day RSI | 34.17 | |||||
| 14-Day RSI | 37.54 | |||||
| 3-1 Month Momentum % | -4.21 | |||||
| 6-1 Month Momentum % | 25.67 | |||||
| 12-1 Month Momentum % | 36.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.24 | |||||
| Quick Ratio | 3.08 | |||||
| Cash Ratio | 2.78 | |||||
| Days Inventory | 337.24 | |||||
| Days Sales Outstanding | 47.67 | |||||
| Days Payable | 186.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.3 | |||||
| Shareholder Yield % | -0.03 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 89.73 | |||||
| Operating Margin % | -204.04 | |||||
| Net Margin % | -200.24 | |||||
| FCF Margin % | -95.61 | |||||
| ROE % | -178.94 | |||||
| ROA % | -75.35 | |||||
| ROIC % | -600 | |||||
| 3-Year ROIIC % | -187.25 | |||||
| ROC (Joel Greenblatt) % | -7019.38 | |||||
| ROCE % | -88.83 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 25.77 | |||||
| PB Ratio | 157.79 | |||||
| Price-to-Tangible-Book | 219.64 | |||||
| EV-to-EBIT | -13.73 | |||||
| EV-to-Forward-EBIT | -26.88 | |||||
| EV-to-EBITDA | -13.8 | |||||
| EV-to-Revenue | 25.34 | |||||
| EV-to-Forward-Revenue | 18.17 | |||||
| EV-to-FCF | -26.51 | |||||
| Price-to-GF-Value | 0.61 | |||||
| Price-to-Net-Current-Asset-Value | 915.17 | |||||
| Price-to-Net-Cash | 36.85 | |||||
| Earnings Yield (Greenblatt) % | -7.28 | |||||
| FCF Yield % | -3.58 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RYTM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Rhythm Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 130.126 | ||
| EPS (TTM) ($) | -4.35 | ||
| Beta | 2.62 | ||
| 3-Year Sharpe Ratio | 0.91 | ||
| 3-Year Sortino Ratio | 2.94 | ||
| Volatility % | 45.58 | ||
| 14-Day RSI | 37.54 | ||
| 14-Day ATR ($) | 2.179572 | ||
| 20-Day SMA ($) | 57.3765 | ||
| 12-1 Month Momentum % | 36.87 | ||
| 52-Week Range ($) | 35.17 - 68.58 | ||
| Shares Outstanding (Mil) | 62.39 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Rhythm Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Rhythm Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Rhythm Pharmaceuticals Inc Frequently Asked Questions
What is Rhythm Pharmaceuticals Inc(RYTM)'s stock price today?
The current price of RYTM is $54.91. The 52 week high of RYTM is $68.58 and 52 week low is $35.17.
When is next earnings date of Rhythm Pharmaceuticals Inc(RYTM)?
The next earnings date of Rhythm Pharmaceuticals Inc(RYTM) is 2025-05-07 Est..
Does Rhythm Pharmaceuticals Inc(RYTM) pay dividends? If so, how much?
Rhythm Pharmaceuticals Inc(RYTM) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers